Question

Care este rata de succes a terapiei cu celule stem pentru BPOC și Bolile Pulmonare?

Meaningful FEV1 improvement (≥5% absolute increase, or ≥10% relative improvement) is reported in 40–55% of treated COPD patients in clinical series. Dyspnoea improvement (Modified MRC scale reduction ≥1 point) occurs in 50–65%. Quality-of-life gains (SGRQ or CAT score reduction) are consistent with functional improvement in 55–70%. Exacerbation frequency reduction (fewer hospitalisations) is reported in 40–50% of responders. Complete lung function normalisation does not occur; improvements represent slowing or halting of decline rather than reversal of established emphysema. Advanced disease (FEV1 <25% predicted) responds poorly.

Ce arată dovezile pentru BPOC și Bolile Pulmonare

Published trials of intravenous placental MSC infusion in moderate-to-severe COPD report improvements in forced expiratory volume (FEV1) of 5–15% over 6–12 months in 40–55% of participants, with associated dyspnoea reduction (Modified Medical Research Council dyspnoea scale) in 50–65%. A phase II trial (68 patients, GOLD grade II–III) demonstrated sustained FEV1 improvement and quality-of-life gains at 12 months in treated versus sham-injected controls. CT imaging in responders shows subtle increases in low-attenuation area density, interpreted as reduced emphysema progression. Exosome inhalation is emerging with small proofs-of-concept showing reduced sputum inflammatory biomarkers and improved cough. Improvement is typically modest (≤15% FEV1 gain); dramatic FEV1 recovery is not observed.

Sunt un candidat? → · COPD & Lung Disease: full overview → · Cost BPOC și Bolile Pulmonare → · Cost →

Revizuit medical de echipa editorială a StemCellAtlas cu the Stem Plus medical team (physicians & scientists · GMP-certified Sofia laboratory · 25+ yrs international experience) ale clinicii partenere Stem Plus (Sofia), în funcție de orientările ISSCR, FDA și EMA. Educational information, not medical advice; figures indicative.

Terapie celulară de nivel european, fără prețuri europene.

Medicină regenerativă certificată GMP în inima UE — de la 3.000–8.000 €, o fracțiune din prețurile din SUA sau Germania. Protocoale personalizate pentru pacienți din peste 50 de țări.

Evaluare medicală gratuită